The prevalence of migraine in multiple sclerosis (MS): A systematic review and meta-analysis

Mirmosayyeb, Omid; Barzegar, Mahdi; Nehzat, Nasim; Shaygannejad, Vahid; Sahraian, Mohammad Ali; Ghajarzadeh, Mahsa

doi:10.1016/j.jocn.2020.06.021

Cited by 28 publications

(19 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…majority of the NID group). 18 Notably, there was no new side effect signal for either the NID or control group when compared to published SARS-CoV-2 vaccine trials.…”

Section: Discussionmentioning

confidence: 93%

Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data

Epstein

Xia

Lee

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…majority of the NID group). 18 Notably, there was no new side effect signal for either the NID or control group when compared to published SARS-CoV-2 vaccine trials.…”

Section: Discussionmentioning

confidence: 93%

Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data

Epstein

Xia

Lee

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

show abstract

“…However, when only MwA was considered, sensitivity analysis evidenced a significant association between this subtype of migraine and MS with an OR = 2.29 without a significant heterogeneity. A more recent meta-analysis including 11 articles and 12 abstracts conference papers found a pooled prevalence of migraine of 31.1% in a total of 11,372 MS cases, with a large variability among residents of different countries in the world [ 78 ].…”

Section: Headache and Multiple Sclerosismentioning

confidence: 99%

Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms

Biscetti

Vanna

Cresta

et al. 2021

J Neuroinflammation

View full text Add to dashboard Cite

Several lines of evidence support a role of the immune system in headache pathogenesis, with particular regard to migraine. Firstly, alterations in cytokine profile and in lymphocyte subsets have been reported in headache patients. Secondly, several genetic and environmental pathogenic factors seem to be frequently shared by headache and immunological/autoimmune diseases. Accordingly, immunological alterations in primary headaches, in particular in migraine, have been suggested to predispose some patients to the development of immunological and autoimmune diseases. On the other hand, pathogenic mechanisms underlying autoimmune disorders, in some cases, seem to favour the onset of headache. Therefore, an association between headache and immunological/autoimmune disorders has been thoroughly investigated in the last years. The knowledge of this possible association may have relevant implications in the clinical practice when deciding diagnostic and therapeutic approaches. The present review summarizes findings to date regarding the plausible relationship between headache and immunological/autoimmune disorders, starting from a description of immunological alteration of primary headaches, and moving onward to the evidence supporting a potential link between headache and each specific autoimmune/immunological disease.

show abstract

“…It is generally more prevalent among women and younger people and deteriorates patients’ lifestyles in every manner ranging from personal, social, occupational, to marital aspects. (1,2) MS can be classified based on its clinical manifestation and course of progression, as there are many differences in the manifestation of MS between different patients of different ages, genders, races, genetic, and even geographical backgrounds. However, symptoms associated with MS ordinarily pivot around sensory and motor dysfunctions.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of dysphagia in patients with multiple sclerosis; a systematic review and meta-analysis

Mirmosayyeb

Ebrahimi

Shekarian

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Objectives: Dysphagia is a major comorbidity observed in patients with multiple sclerosis, yet different prevalence rates are reported for it. Therefore, we have designed this systematic review to estimate the pooled prevalence of dysphagia in patients with MS. Method: We searched PubMed, Scopus, EMBASE, Web of Science, and gray literature including references from the identified studies, reviews studies, and conference abstracts which were published up to February 2021. Articles that were relevant to our topic and could provide information regarding the prevalence of dysphagia among MS patients were included; however, articles with self-report screening strategies were excluded. Results: The literature search found 1993 articles. After eliminating duplicates, 1272 articles remained. Sixteen abstract conference papers were included for final analysis. A total of 10846 MS cases and 4913 MS patients with dysphagia included in the analysis. The pooled prevalence of dysphagia in the included studies was 45.3% (95% CI: [40.7%-50%]) Conclusion: The results of this systematic review shows that the prevalence of dysphagia in MS patients is 45% which is greatly higher compared to the general population.

show abstract

The prevalence of migraine in multiple sclerosis (MS): A systematic review and meta-analysis

Cited by 28 publications

References 33 publications

Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data

Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data

Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms

Prevalence of dysphagia in patients with multiple sclerosis; a systematic review and meta-analysis

Contact Info

Product

Resources

About